Multiple anti-tumor effects of Reparixin on thyroid cancer

• DOI: 10.18632/oncotarget.16412
• Publication Date: 2017-03-21T14:30:06Z
• Authors: Federica Liotti; Maria De Pizzol; Marcello Allegretti; Nella Prevete; Rosa Marina Melillo
• Keywords: CXC chemokine receptors

// Federica Liotti 1 , Maria De Pizzol 2 Marcello Allegretti Nella Prevete 3, 4 Rosa Marina Melillo 1, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, University of Naples "Federico II", Naples, Italy Dompé Farmaceutici S.p.A., L'Aquila, 3 Scienze Mediche Traslazionali, Istituto Endocrinologia ed Oncologia Sperimentale del CNR "G. Salvatore", Correspondence to: Melillo, email: [e-mail] Prevete, [e-mail] Keywords: Reparixin, thyroid cancer, CXCR1, CXCR2 Received: October 19, 2016 Accepted: March 11, 2017 Published: 21, ABSTRACT Background: Expression IL-8 and its receptors CXCR1 is a common occurrence in human epithelial cancer (TC). In TC samples, expression associated with tumor progression. enhances proliferation, survival, motility, leads to the maintenance stemness features tumor-initiating ability cells. Here, we studied effects Reparixin (formerly Repertaxin), small molecular weight inhibitor, on malignant phenotype various cell lines. Results: impaired viability cancerous cells, but not that non-malignant counterpart. treatment significantly decreased Epithelial-to-Mesenchymal Transition (EMT) stemness. silencing abolished these effects. sensitized cells Docetaxel Doxorubicin culture. Used as single agent, inhibited tumorigenicity immunodeficient mice. Finally, potentiated xenotransplants Materials Methods: We assessed (by growth curves, BrdU incorporation, TUNEL assay), EMT RT-PCR, Flow Cytometry, Migration assays), sphere-formation self-renewal), xenotransplantation nude mice). Conclusions: The present study suggests both alone combination classic chemotherapics, represents novel potential therapeutic strategy for aggressive forms TC.